September 20, 2013 - The court granted defendants' motion to dismiss with prejudice.
September 4, 2012 - Defendants filed a motion to dismiss.

July 6, 2012 - The lead plaintiffs filed an amended consolidated complaint.

April 26, 2012 - Lead plaintiffs and lead counsel were appointed.

April 3, 2012 - Lead plaintiff motions were filed.

February 3, 2012 - An investor in shares of GenVec Inc (NASDAQ: GNVC) filed a lawsuit in the U.S. District Court for the District of Maryland against GenVec Inc over alleged Violations of Federal Securities Laws in connection with certain statements.

According to the complaint the plaintiff alleges on behalf of all investors who purchased or otherwise acquired GenVec Inc (NASDAQ: GNVC) common stock between March 12, 2009 and March 30, 2010, that GenVec Inc and certain of its officers violated the Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Specifically the plaintiff alleges that between March 12, 2009 and March 30, 2010, GenVec Inc and its most senior officers continuously touted the clinical success of TNFerade, and that it was the company's lead product candidate with strategic commercial value.

On March 12, 2009, GenVec Inc (NASDAQ: GNVC) announced its financial results for the fourth quarter and year ended December 31, 2008. Among other things, GenVec Inc said that it “announced encouraging top-line results of an interim analysis from our Phase III Pancreatic Cancer Clinical Trial (PACT). An independent Data Safety Monitoring Board reviewed the interim analysis data and recommended the trial continue as planned.”

Then on March 29, 2010, GenVec Inc (NASDAQ: GNVC) announced that it is discontinuing its Phase 3 clinical trial of TNFerade(TM) in patients with locally advanced pancreatic cancer based on results of an interim analysis.

GenVec Inc said that this interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.

GenVec Inc said that it has determined, after conferring with its independent Data Safety Monitoring Board, that the PACT trial would not meet the goal of demonstrating persuasive evidence of clinical effectiveness that could form the basis for regulatory approval in the population chosen for study.

GenVec Inc reported that its annual Revenue rose from $13.86million in 09 to $16.47million in 2010 and its Net Loss decreased from $18.36million in 2009 to $12.27million in 2010. Despite a slight decrease in its third quarter Revenue from $5.16million for 2010 to $4.33million for 2011. GenVec Inc reported that it was able to decrease its third quarter Net Loss from $2.38million in 2010 to $1.48million in 2011.

Shares of GenVec Inc increased after its 1:20 split on April 19, 2011 to $5.00 per share on May 2, 2011, but fell on August 10, 2010 to as low as $2.10 per share.